Literature DB >> 27795370

Efficacy of Doxycycline in the Treatment of Syphilis.

Ting Dai1, Rui Qu1, Jinfen Liu1, Pingyu Zhou2, Qianqiu Wang3.   

Abstract

Doxycycline is an alternative antibiotic drug for the treatment of syphilis, but data on its efficacy, especially data on its efficacy against late latent syphilis, are limited. A retrospective study was conducted to evaluate the effectiveness of doxycycline for the treatment of patients with different stages of syphilis. Patients who received doxycycline treatment between June 2011 and June 2014 were involved. The serological response to doxycycline was defined as either a negative toluidine red unheated serum test (TRUST) result or a ≥4-fold decrease in titer at 12 months following the treatment. Univariate and multivariate logistic regression analyses were performed to identify factors associated with the serological response. During the study period, a total of 163 syphilis patients were treated with doxycycline, and 118 patients completed doxycycline treatment and the 12-month follow-up. Among the 118 patients, the serological response rate at 12 months was 100.0% (7/7) in patients with primary syphilis, 96.9% (62/64) in patients with secondary syphilis, 91.3% (21/23) in patients with early latent syphilis, and 79.2% (19/24) in patients with late latent syphilis. The total serological response rates were 92.4% (109/118) for preprotocol (PP) patients and 66.9% (109/163) for all intention-to-treat (ITT) patients. In multivariate analysis, patients who serologically responded at 12 months following treatment were positively associated with a higher baseline TRUST titer and an earlier syphilis stage than nonresponders. Our study showed excellent treatment outcomes in patients with different stages of syphilis. Our data, along with those from other reports, support the usage of doxycycline as a good alternative therapeutic option in the treatment of syphilis.
Copyright © 2016 American Society for Microbiology.

Entities:  

Keywords:  doxycycline; efficacy; syphilis

Mesh:

Substances:

Year:  2016        PMID: 27795370      PMCID: PMC5192147          DOI: 10.1128/AAC.01092-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Azithromycin treatment failure among primary and secondary syphilis patients in Shanghai.

Authors:  Pingyu Zhou; Kang Li; Haikong Lu; Yihong Qian; Xin Gu; Weiming Gong; Joseph D Tucker; Myron S Cohen
Journal:  Sex Transm Dis       Date:  2010-11       Impact factor: 2.830

2.  Serological response to syphilis treatment in HIV-positive and HIV-negative patients attending sexually transmitted diseases clinics.

Authors:  K G Ghanem; E J Erbelding; Z S Wiener; A M Rompalo
Journal:  Sex Transm Infect       Date:  2006-08-30       Impact factor: 3.519

3.  Comparative bioavailability of doxycycline.

Authors:  J D Arcilla; J L Fiore; O Resnick; J W Nadelmann; J L Huth; W M Troetel
Journal:  Curr Ther Res Clin Exp       Date:  1974-10

4.  High prevalence of macrolide resistant Treponema pallidum strains in a London centre.

Authors:  Craig Tipple; Myra O McClure; Graham P Taylor
Journal:  Sex Transm Infect       Date:  2011-10       Impact factor: 3.519

5.  A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis.

Authors:  Edward W Hook; Frieda Behets; Kathleen Van Damme; Noro Ravelomanana; Peter Leone; Arlene C Sena; David Martin; Carol Langley; Linda McNeil; Mark Wolff
Journal:  J Infect Dis       Date:  2010-06-01       Impact factor: 5.226

6.  Factors determining serologic response to treatment in patients with syphilis.

Authors:  Julio J González-López; Manuel L Fernández Guerrero; Rodolfo Luján; Sagrario Fernández Tostado; Miguel de Górgolas; Luis Requena
Journal:  Clin Infect Dis       Date:  2009-11-15       Impact factor: 9.079

7.  Early syphilis: serological treatment response to doxycycline/tetracycline versus benzathine penicillin.

Authors:  Jun Li; He-Yi Zheng
Journal:  J Infect Dev Ctries       Date:  2014-02-13       Impact factor: 0.968

8.  Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features.

Authors:  Christina M Marra; Clare L Maxwell; Stacy L Smith; Sheila A Lukehart; Anne M Rompalo; Molly Eaton; Bradley P Stoner; Michael Augenbraun; David E Barker; James J Corbett; Mark Zajackowski; Charles Raines; Judith Nerad; Romina Kee; Scott H Barnett
Journal:  J Infect Dis       Date:  2004-01-27       Impact factor: 5.226

9.  High frequency of the 23S rRNA A2058G mutation of Treponema pallidum in Shanghai is associated with a current strategy for the treatment of syphilis.

Authors:  Haikong Lu; Kang Li; Weimin Gong; Limeng Yan; Xin Gu; Ze Chai; Zhifang Guan; Pingyu Zhou
Journal:  Emerg Microbes Infect       Date:  2015-02-11       Impact factor: 7.163

10.  Comparison of serological response to doxycycline versus benzathine penicillin G in the treatment of early syphilis in HIV-infected patients: a multi-center observational study.

Authors:  Jen-Chih Tsai; Yu-Huei Lin; Po-Liang Lu; Ni-Jiin Shen; Chia-Jui Yang; Nan-Yao Lee; Hung-Jen Tang; Yuag-Meng Liu; Wen-Chi Huang; Chen-Hsiang Lee; Wen-Chien Ko; Yen-Hsu Chen; Hsi-Hsun Lin; Tun-Chieh Chen; Chien-Ching Hung
Journal:  PLoS One       Date:  2014-10-13       Impact factor: 3.240

View more
  7 in total

1.  In Vitro Susceptibility of Treponema pallidum subsp. pallidum to Doxycycline.

Authors:  Diane G Edmondson; Gary P Wormser; Steven J Norris
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

2.  Management of Adult Syphilis: Key Questions to Inform the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines.

Authors:  Susan Tuddenham; Khalil G Ghanem
Journal:  Clin Infect Dis       Date:  2022-04-13       Impact factor: 9.079

3.  The great imitator, revisited.

Authors:  Nikhil Oliveira; Lorraine Joseph Kandathil; Georgi Tchernev
Journal:  Dermatol Reports       Date:  2021-10-05

4.  The resurgence of syphilis in high-income countries in the 2000s: a focus on Europe.

Authors:  G Spiteri; M Unemo; O Mårdh; A J Amato-Gauci
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451

Review 5.  Cutaneous Rosai - Dorfman disease in a patient with late syphilis and cervical cancer - case report and a review of literature.

Authors:  Angelika Bielach-Bazyluk; Agnieszka B Serwin; Agata Pilaszewicz-Puza; Iwona Flisiak
Journal:  BMC Dermatol       Date:  2020-12-07

6.  Doxycycline Hyclate Modulates Antioxidant Defenses, Matrix Metalloproteinases, and COX-2 Activity Accelerating Skin Wound Healing by Secondary Intention in Rats.

Authors:  Luciana S Altoé; Raul S Alves; Lyvia L Miranda; Mariáurea M Sarandy; Daniel S S Bastos; Elda Gonçalves-Santos; Rômulo D Novaes; Reggiani V Gonçalves
Journal:  Oxid Med Cell Longev       Date:  2021-04-17       Impact factor: 6.543

7.  Analysis of serological treatment response to doxycycline versus benzathine penicillin in syphilis infections, a retrospective single-center study.

Authors:  Corrado Zengarini; Miriam Anna Carpanese; Giulio Vara; Alice Conni; Bianca Maria Piraccini; Valeria Gaspari
Journal:  Dermatol Ther       Date:  2022-06-05       Impact factor: 3.858

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.